^
    4ms
    Predictive Biomarkers for Response to TGF- β Inhibition in Resensitizing Chemo(radiated) Esophageal Adenocarcinoma. (PubMed, Pharmacol Res)
    TGF-β inhibitors fresolimumab and A83-01 were employed to inhibit EMT, and mesenchymal markers were quantified via flow cytometry to assess efficacy...Our findings reveal a distinct gene expression pattern associated with the response to TGF-β inhibition in chemo(radiated) EAC. The identified DEGs and predictive markers may assist patient selection in clinical studies investigating TGF-β targeting.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    fresolimumab (GC 1008)
    1year
    In-silico prediction of TGF-β1 non-synonymous variants and their impact on binding affinity to Fresolimumab. (PubMed, J Biomol Struct Dyn)
    Among them, the E35D variant significantly destabilized the TGF-β1 protein structure, resulting in rearrangement in the binding site and affecting the interactions with the Fresolimumab. This study identified four variants that can affect the TGF-β1 protein structure and result in functional consequences such as impaired response to Fresolimumab.Communicated by Ramaswamy H. Sarma.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    fresolimumab (GC 1008)
    over2years
    Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses. (PubMed, J Immunother Cancer)
    BA more effectively blocks TGF-β by targeting TGF-β trap to the tumor via PD-L1 binding. Such colocalized targeting elicits distinct and superior antitumor responses relative to single agent combination therapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 expression
    |
    bintrafusp alfa (M7824) • fresolimumab (GC 1008)